Evidence map›Paper›PMID 41311505›Full record

ReviewFrontiers in cardiovascular medicine2025

Vasorin at the crossroads: charting new paths in preeclampsia research.

Saravanakumar Murugesan, Lakshmi Saravanakumar, Jose Carlose Fernandez-Morales, Tamas Jilling, Dan E Berkowitz

Abstract readReview
In one paragraph

Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Saravanakumar MurugesanDepartment of Anesthesiology and Perioperative Medicine, Division of Molecular and Translational Biomedicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Lakshmi SaravanakumarDepartment of Anesthesiology and Perioperative Medicine, Division of Molecular and Translational Biomedicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Jose Carlose Fernandez-MoralesDepartment of Anesthesiology and Perioperative Medicine, Division of Molecular and Translational Biomedicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Tamas JillingDepartment of Pediatrics, Division of Neonatology, University of Alabama at Birmingham, Birmingham, AL, United States.
Dan E BerkowitzDepartment of Anesthesiology and Perioperative Medicine, Division of Molecular and Translational Biomedicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Preeclampsia (PE) remains a leading cause of maternal and fetal morbidity and mortality worldwide, yet the precise molecular mechanisms driving its pathology are not fully understood. Recent research has established extracellular vesicles (EVs) as critical mediators in the development of PE-related vascular dysfunction. These nanosized, lipid-bound particles are secreted by cells and serve as a sophisticated system of intercellular communication, carrying functionally active cargo-including proteins, nucleic acids, and lipids-that can modulate physiological and pathological processes via autocrine, paracrine, and endocrine signaling. While the role of EVs-mediated communication in PE has been extensively studied, the specific functions of individual protein components within this cargo remain largely unexplored. Vasorin (VASN), a known regulator of the TGF-β signaling pathway, is a promising candidate for investigation in pregnancy disorder. This review synthesizes existing evidence on VASN's role in PE and discusses its potential contributions to disease pathogenesis. We will highlight the critical need for future research to elucidate VASN's function and evaluate its activity as a promising new therapeutic strategy for a spectrum of pregnancy-related disorders.

Indexed as

endothelial dysfunctionplacentapreeclampsiaTGF-βVASN

Identifiers

PMID41311505
PMCPMC12647036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.